Clinical Trial Search

Primary: Percentage of Participants Persistent With Denosumab Injections at 12 Months and 24 Months — 92.2; 89.3; 94.3; 95.7 percentage of participants

Primary: Cmax - Maximum Plasma Concentration of Levodopa — 1047; 1203; 1030; 1057 ng/mL

Primary: Physician's Knowledge and Recommendations to Their Patients on Appropriate Dosing and Minimizing the Risk of Bleeding When Treated With Pradaxa® (Questionnaire) — 65…

Primary: International Cooperative Ataxia Rating Scale (ICARS) — 39; 30; 47; 46 units

Primary: Achievement of ≥90% Reduction From Baseline PASI Score (PASI90) at Week 12 — 32.6; 73.2; 81.0; 77.1 Percentage of participants — p=<0.0001

Primary: Bacilli Negative Conversion Rate — 269 participants

Primary: Cumulative Incidence of Grade II to IV Acute GVHD — 53 percentage of incidence

Primary: Mean Residual Peroxide at Day 30 — 229.7; 26.2 parts per million (ppm)

Primary: 6-month Progression-free Survival Rate — 24.5; 46.6 percentage of participants — p=0.005

Primary: Percentage of Participants With Cardiac and Liver Iron Overload. — 10; 22; 4; 0 Percentage of participants

Primary: AUC0-inf — 1150; 1430; 5060 nmol*h/L

Primary: Number of Participants Reporting One or More Adverse Drug Reactions — 1; 0; 1; 0 participants

Primary: To Reduce the Use of Health Care Services by Quantifying the Number of Hospitalizations — 12; 1 Hospitalizations

Primary: Percentage of Participants Initiating Boceprevir Plus PR Treatment, Telaprevir Plus PR Treatment, or PR Treatment Alone (Drug Utilization Pattern) — 43.9; 45.2; 10.9…

Primary: Objective Response Rate (ORR) Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) — 30; 25 percentage of participants